Posted by Michael Wonder on 18 Dec 2017
Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Yervoy (ipilimumab) for the treatment of paediatric patients 12 years and older with unresectable or metastatic melanoma
18 December 2017 - First positive CHMP opinion for an immuno-oncology agent for paediatric patients.
Bristol-Myers Squibb Company announced today that the CHMP of the EMA has recommended the approval of Yervoy (ipilimumab) for paediatric patients 12 years of age and older who have unresectable or metastatic melanoma.
The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.
